February 25, 2025 — Rockville, MD — Psomagen Inc. is delighted to announce the latest advancement of our capabilities with the addition of Ultima Genomics’ UG 100™ next generation sequencer, and that we have attained Certified Service Provider (CSP) status with Ultima.
Psomagen’s Chief Executive Officer Dr. Su Hong comments, “With over two decades of experience in genomics research and clinical diagnostics, Psomagen has consistently delivered high-quality multiomics data to the scientific community. Our integration of Ultima Genomics' UG 100™ sequencer enhances our capabilities, allowing us to offer more comprehensive and cost-effective solutions. This synergy positions us to better support researchers in making groundbreaking discoveries in genomics.”
Adding High Output Capacity to a North American Leader in Multiomics:
The UG 100 will offer rapid run times at a reduced cost compared to other high throughput sequencing instruments. The Ultima UG 100 will add >12,000 genomes per year to Psomagen’s existing fleet of high output sequencers, now totaling over 100,000 genomes a year. UG 100’s variant callers can process ~40 genomes in 2 hours. The system has the potential to reduce running costs and give researchers access to NGS and other multiomic applications.
Enhancing Psomagen’s Single Cell Services:
Psomagen has been offering full workflow single-cell services since it became a 10x Genomics CSP, and has added services from BioSkryb, ScaleBio, Fluent BioSciences, and Parse Bio. Adding the UG 100 will help reduce costs of counting applications per 1M reads compared to existing technologies. The capabilities will add to Psomagen’s Single Cell and Spatial Center of Excellence at its Rockville, MD facility supporting spatial biology methods like the 10x Visium HD platform. Likewise, the UG 100 will enable higher throughput chemistries like ScaleBio’s new QuantumScale™ single-cell RNA kit, and Parse Bio’s GigaLab™ kit. Ultima Genomics and the Chan Zuckerberg Initiative recently announced its ambitious goal to sequence 1 billion single cells utilizing 10x Genomics’s GEM-X platform.
Matt Kramer, V.P. of Sales & Marketing at Psomagen, says, “The UG 100 gives our customers alternatives to achieve their research goals. Psomagen’s production efficiencies match with Ultima’s objectives to deliver multiomic solutions at cost-efficient scale. We look forward to expanding our services to include the UG 100.”
High Content Proteomics — Olink® Explore HT and Reveal:
As an Olink Certified Service Provider, Psomagen has been providing Olink Target 48/96 through Explore HT offerings for several years now. The UG 100 has the ability to reduce the cost per analyte compared to past sequencing output, making Olink’s chemistry accessible to even more researchers, or enabling a new scale of research. As an example, Ultima Genomics recently announced that the UG 100 Sequencing Platform was selected for UK Biobank's Groundbreaking Human Proteome Study which aims to process approximately 600,000 samples.
Achieving High Sensitivity and Accuracy Sequencing Output:
The UG 100 has a proprietary feature called paired plus minus sequencing, or ppmSeq, providing improved variant calling with reduced errors to one part per million or better. This empowers scientists to start tackling some of biology’s most challenging problems. This feature will help Psomagen meet its customers’ needs for many emerging applications such as cell-free DNA for residual disease applications. The UG 100 brings cost-efficient technology for whole genome tumor variant profiling, resulting in large mutational profiles that can be monitored in plasma over time.
Enabling AI & Machine Learning at Scale:
The scale and cohesion of the UG 100’s output make it possible to deliver a volume of data with greater consistency than past efforts to better enable researchers to train AI models and make transformative discoveries across precision medicine and functional genomics. Single-cell datasets from the UG 100 will bring critical new data and resolution to multiple domains of biology that need comprehensive resources such as mapping genetic perturbations across diverse cell types and tissues.
About Psomagen
Psomagen, Inc., formerly Macrogen U.S.A., is a North American integrative omics solutions and contract laboratory services provider. The company makes cutting-edge technology and data analysis accessible to the academic, pharma, biotech and clinical markets. With both CLIA-certified and CAP-accredited facilities, its team delivers the highest-quality multiomics data using best-in-class DNA, RNA, and protein analysis systems. In conjunction with its bioinformatics capabilities, Psomagen offers a path to insights that is both simple and affordable. Learn more at psomagen.com.
Contact
Matt Kramer
V.P. of Sales & Marketing
Psomagen, Inc.
matt.kramer@psomagen.com
About Ultima Genomics
Ultima Genomics mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. Ultima is challenging conventional next-generation sequencing technologies, with its new sequencing architecture designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit www.ultimagenomics.com.
